To date no biological treatment options specifically targeting the hypoxic nature of chronic wounds have been developed and marketed. While administration of individual angiogenic factors may stimulate some aspects of angiogenesis, the simultaneous expression of multiple factors is required to promote morphologically and functionally normal vessels. In this Phase II study, we propose to characterize a human keratinocyte cell line genetically-modified to coordinately express elevated levels of multiple therapeutic factors. Advances in ex vivo genetic engineering of a patented human keratinocyte cell line at Stratatech Corporation has made it uniquely positioned to complete this work. If successful, the proposed research will ultimately lead to the development and commercialization of improved treatments to promote the healing of chronic wounds and other severe skin defects.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
3R44AG026903-04S2
Application #
7914709
Study Section
Special Emphasis Panel (ZRG1-SSMI-K (10))
Program Officer
Williams, John
Project Start
2009-09-15
Project End
2010-08-31
Budget Start
2009-09-15
Budget End
2010-08-31
Support Year
4
Fiscal Year
2009
Total Cost
$99,916
Indirect Cost
Name
Stratatech Corporation
Department
Type
DUNS #
160392168
City
Madison
State
WI
Country
United States
Zip Code
53719